A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2010 by National University Hospital, Singapore.
Recruitment status was Not yet recruiting

Sponsor:

Information provided by:

National University Hospital, Singapore

ClinicalTrials.gov Identifier:

NCT01100827

First received: April 7, 2010

Last updated: April 8, 2010

Last verified: April 2010

History of Changes

Purpose

To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC.

To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.

Condition	Intervention
NSCLC	Other: EGFR mutation status in patients

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Retrospective

Resource links provided by NLM:

Genetics Home Reference related topics: Help Me Understand Genetics

MedlinePlus related topics: Cancer Lung Cancer

U.S. FDA Resources

Further study details as provided by National University Hospital, Singapore:

Groups/Cohorts	Assigned Interventions
EGFR mutation status in patients	Other: EGFR mutation status in patients

Eligibility

Ages Eligible for Study:	1 Year and older
Genders Eligible for Study:	Both
Sampling Method:	Probability Sample

Study Population

In order to determine the EGFR mutation status, data analysis will be performed on demographic data and medical records (i.e. case notes and pathology reports) from patient with advanced stage adenocarcinoma NSCLC

Criteria

Inclusion Criteria:

Nil

Exclusion Criteria:

Nil

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01100827

Contacts

Contact: Ross Andrew Soo, MBBS

65 6772 4624

ross_soo@nuhs.edu.sg

Locations

Singapore
National University Hospital Singapore	Not yet recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS 65 6772 4624 ross_soo@nuhs.edu.sg

Sponsors and Collaborators

National University Hospital, Singapore

More Information

Publications:

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004 Mar 15;22(6):1103-9.

ClinicalTrials.gov Identifier:	NCT01100827 History of Changes
Other Study ID Numbers:	NS01/03/10
Study First Received:	April 7, 2010
Last Updated:	April 8, 2010
Health Authority:	Singapore: Domain Specific Review Boards

Keywords provided by National University Hospital, Singapore:

EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC
The association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.

Additional relevant MeSH terms:

Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic

Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 17, 2012

To Top